ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluconazole

Also written as “fluconazole”, “Fluconazole 400 mg” and “Diflucan®”.

Its studies are mostly in Meningitis, Cryptococcal · Candidiasis · Candidiasis, Oral · Candidemia · Lymphoma, led by 8 companies.

Drug pageFluconazole: every studyMany companies study it; this page follows only the 37 they lead. All 104 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Nov 2, 199937 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer260 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Merckits history only30 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
AstraZenecaits history only20 open or runningphase 1since Mar 20, 2014Mar 20, 2014none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Jan 13, 2012Jan 13, 2012none ahead
Bayerits history only10 open or runningphase 1since Apr 17, 2019Apr 17, 2019none ahead
Johnson & Johnsonits history only10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Pharmtechnologyits history only10 open or runningphase 1since Jul 26, 2019Jul 26, 2019none ahead
Sutphin Drugsits history only10 open or runningearly phase 1since Jul 31, 2020Jul 31, 2020none ahead

Also a collaborator on its studies: Altasciences, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene and Vicuron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First studies: 3 phase 3 studiesFirst studyNCT00002339, NCT00002277, NCT00001017
  2. Nov 2, 199916 no phase studiesNCT00002325, NCT00002306, NCT00002305 and 13 more
  3. Mar 11, 2003Phase 3 study in CandidiasisNCT00056368 · 256 enrolled · United States
  4. Mar 25, 2008Phase 3 study in Tinea CapitisNCT00645242 · 185 enrolled · United States, Puerto Rico
  5. May 29, 2008Phase 3 study in Candidiasis, InvasiveNCT00689338 · 216 enrolled · Austria, Belgium, Canada and more
  6. Aug 3, 2010Phase 3 study in CandidemiaNCT01176058 · 17 enrolled · China
  7. Jan 28, 2013Phase 3 study in Candidiasis, VulvovaginalNCT01806623 · 157 enrolled · Japan
  8. Aug 20, 2014Phase 1 study in NeoplasmsNCT02222922 · 138 enrolled · United States, Spain
  9. Aug 3, 2018Phase 1 study in BioequivalenceNCT03621072 · 36 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule

Studies

All 26 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03621072Bioequivalence · China1CompletedJul 20, 201936
NCT02222922Neoplasms · United States, Spain1CompletedNov 5, 2019138
NCT01806623Candidiasis, Vulvovaginal · Japan3CompletedNov 22, 2013157
NCT01176058Candidemia · China3TerminatedNov 201117
NCT00689338Candidiasis, Invasive · Austria, Belgium, Canada and more3CompletedMay 2010216
NCT00645242Tinea Capitis · United States, Puerto Rico3Completed185
NCT00056368Candidiasis · United States3Completed256
NCT00002339Candidiasis · United States3Completed100
NCT00002325Mycoses · United States–Completed
NCT00002306Meningitis, Cryptococcal · United States–Completed
NCT00002305Meningitis, Cryptococcal · United States, Canada–Completed
NCT00002304Candidiasis · United States, Canada–Completed
NCT00002294Meningitis, Cryptococcal · United States–Completed
NCT00002282Candidiasis, Oral · United States–Completed
NCT00002277Mycoses · United States3Completed
NCT00002113Meningitis, Cryptococcal · United States–Completed64
NCT00002112Candidiasis, Oral · United States–Completed
NCT00002077Meningitis, Cryptococcal · United States–Completed
NCT00002076Meningitis, Cryptococcal · United States–Completed
NCT00002075Meningitis, Cryptococcal · United States–Completed
NCT00002074Meningitis, Cryptococcal · United States, Canada–Completed
NCT00002068Meningitis, Cryptococcal · United States, Canada–Completed
NCT00002040Meningitis, Cryptococcal · United States–Completed
NCT00002038Candidiasis · United States–Completed
NCT00002010Meningitis · United States–Completed
NCT00001017Meningitis, Cryptococcal · United States3CompletedJul 1991330

How it is read

Names in the registry

  • “Fluconazole”, 36 entries
  • “fluconazole”, 5 entries
  • “Fluconazole 400 mg”, 1 entry
  • “Diflucan®”, 1 entry
  • “Fluconazole 150mg Capsule Localized Originator”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.